Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study

Affiliations

¹ Sorbonne University, AP-HP, Hôpital de La Pitié-Salpêtrière, INSERM UMRS 1136, Paris, France.
² Paris IBD Center, Groupe hospitalier privé Ambroise Paré-Hartmann, Neuilly sur Seine, France.
³ Rheumatology Department, Centre Hospitalier Universitaire d'Orléans, Orléans, France.
⁴ Hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre, France.
⁵ Département de Gastroentérologie, CHU Amiens, Amiens, France.
⁶ Clinique François Chénieux, Limoges, France.
⁷ INSERM, UMR 1229, RMeS, Regenerative Medicine and Skeleton, Université de Nantes, ONIRIS, Nantes, France.
⁸ Odontology Department, University of Nantes, Nantes, France.
⁹ Rheumatology Department, CHU de Nantes, Nantes, France.
¹⁰ Département de Gastroentérologie, Clinique Jules Verne, Nantes, France.
¹¹ Rheumatology Department, Lyon Sud Hospital, Hospices Civils de Lyon, University of Lyon, Lyon, France.
¹² INSERM UMR 1033, Lyon Immunopathology Federation, Lyon, France.
¹³ Sanoïa e-Health Services, 188 av 2nd Division Blindée, 13420, Gémenos, France. bbraithwaite@sanoia.com.
¹⁴ Biogen France SAS, Gastroenterology and Rhumatologie, Biosimilars, Courbevoie, France.
¹⁵ Biogen IDEC, Clinical Research, Biosimilars, Maidenhead, UK.

Published Erratum

Bruno Fautrel et al. Drugs Real World Outcomes. 2025 Mar.

. 2025 Mar;12(1):163-164.

doi: 10.1007/s40801-024-00477-4.

¹ Sorbonne University, AP-HP, Hôpital de La Pitié-Salpêtrière, INSERM UMRS 1136, Paris, France.
² Paris IBD Center, Groupe hospitalier privé Ambroise Paré-Hartmann, Neuilly sur Seine, France.
³ Rheumatology Department, Centre Hospitalier Universitaire d'Orléans, Orléans, France.
⁴ Hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre, France.
⁵ Département de Gastroentérologie, CHU Amiens, Amiens, France.
⁶ Clinique François Chénieux, Limoges, France.
⁷ INSERM, UMR 1229, RMeS, Regenerative Medicine and Skeleton, Université de Nantes, ONIRIS, Nantes, France.
⁸ Odontology Department, University of Nantes, Nantes, France.
⁹ Rheumatology Department, CHU de Nantes, Nantes, France.
¹⁰ Département de Gastroentérologie, Clinique Jules Verne, Nantes, France.
¹¹ Rheumatology Department, Lyon Sud Hospital, Hospices Civils de Lyon, University of Lyon, Lyon, France.
¹² INSERM UMR 1033, Lyon Immunopathology Federation, Lyon, France.
¹³ Sanoïa e-Health Services, 188 av 2nd Division Blindée, 13420, Gémenos, France. bbraithwaite@sanoia.com.
¹⁴ Biogen France SAS, Gastroenterology and Rhumatologie, Biosimilars, Courbevoie, France.
¹⁵ Biogen IDEC, Clinical Research, Biosimilars, Maidenhead, UK.

No abstract available

Erratum for

Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.
Fautrel B, Bouhnik Y, Salliot C, Carbonnel F, Fumery M, Bernardeau C, Maugars Y, Flamant M, Coury F, Braithwaite B, Hateb S, Addison J; PERFUSE investigators. Fautrel B, et al. Drugs Real World Outcomes. 2024 Dec;11(4):573-591. doi: 10.1007/s40801-024-00459-6. Epub 2024 Oct 10. Drugs Real World Outcomes. 2024. PMID: 39384685 Free PMC article.